<DOC>
	<DOCNO>NCT00380159</DOCNO>
	<brief_summary>To assess safety 48 week treatment 10 mg elvucitabine combination background ART subject complete protocol ACH443-014A meet inclusion exclusion criterion .</brief_summary>
	<brief_title>Open-Label , 48 Week Extension Study Elvucitabine Combination With Background ART For Subjects Who Have Completed Study ACH443-014A</brief_title>
	<detailed_description>This study open-label extension study subject complete 14 day treatment protocol ACH443-014A meet inclusion exclusion criterion . Elvucitabine treatment ( 10mg ) begin Day 1 ( Day 15 follow completion protocol ACH443-014A ) consent subject combination background ART determine principal investigator . Subjects clinical laboratory assessment every 2 week first 8 week every 4 week week 48 .</detailed_description>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Subjects complete 14 day treatment ACH443014A , investigator 's judgment , remain candidate receive elvucitabine together background antiretroviral therapy . Failure meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Extension study ACH443-014A</keyword>
</DOC>